Mahesh V. Padval

Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship

Irina M. Shapiro, Vihren N. Kolev, Christian M. Vidal et al. · Science Translational Medicine · 2014 · 244 citations

Medicine, Oncology, Pharmacology +17

PI3K/mTOR Dual Inhibitor VS-5584 Preferentially Targets Cancer Stem Cells

Vihren N. Kolev, Quentin G. Wright, Christian M. Vidal et al. · Cancer Research · 2014 · 128 citations

Medicine, Oncology, Pharmacology +17

A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors

Toshio Shimizu, Kazuya Fukuoka, Masayuki Takeda et al. · Cancer Chemotherapy and Pharmacology · 2016 · 109 citations · Full text

Medicine, Oncology, Pharmacology +16

The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma

Asma Begum, Theodore E. Ewachiw, Clinton Jung et al. · PLoS ONE · 2017 · 83 citations · Full text

Medicine, Cancer Biology, Oncology +17

Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer.

Manish R. Patel, Jeffrey R. Infante, Kathleen N. Moore et al. · Journal of Clinical Oncology · 2014 · 29 citations

Medicine, Oncology, Pharmacology +17